- Home
- IPM vs CMMB Comparison
IPM vs CMMB Comparison
Compare IPM & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPM
- CMMB
- Stock Information
- Founded
- IPM 2005
- CMMB 2004
- Country
- IPM United States
- CMMB Israel
- Employees
- IPM N/A
- CMMB N/A
- Industry
- IPM
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- IPM
- CMMB Health Care
- Exchange
- IPM NYSE
- CMMB Nasdaq
- Market Cap
- IPM 25.2M
- CMMB 23.0M
- IPO Year
- IPM N/A
- CMMB N/A
- Fundamental
- Price
- IPM $1.88
- CMMB $1.21
- Analyst Decision
- IPM Strong Buy
- CMMB Strong Buy
- Analyst Count
- IPM 1
- CMMB 2
- Target Price
- IPM $6.00
- CMMB $9.00
- AVG Volume (30 Days)
- IPM 101.8K
- CMMB 89.3K
- Earning Date
- IPM 05-14-2025
- CMMB 05-27-2025
- Dividend Yield
- IPM N/A
- CMMB N/A
- EPS Growth
- IPM N/A
- CMMB N/A
- EPS
- IPM N/A
- CMMB N/A
- Revenue
- IPM $1,098,280.00
- CMMB N/A
- Revenue This Year
- IPM $2,088.06
- CMMB N/A
- Revenue Next Year
- IPM $11.00
- CMMB N/A
- P/E Ratio
- IPM N/A
- CMMB N/A
- Revenue Growth
- IPM 14.16
- CMMB N/A
- 52 Week Low
- IPM $1.52
- CMMB $0.60
- 52 Week High
- IPM $5.50
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- IPM N/A
- CMMB 46.51
- Support Level
- IPM N/A
- CMMB $1.15
- Resistance Level
- IPM N/A
- CMMB $1.31
- Average True Range (ATR)
- IPM 0.00
- CMMB 0.09
- MACD
- IPM 0.00
- CMMB -0.00
- Stochastic Oscillator
- IPM 0.00
- CMMB 22.58
About IPM INTELLIGENT PROTECTION MANAGEMENT
Intelligent Protection Management Corp is a communications software innovator that powered multimedia social applications.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.